Abridge key facts
as of Oct 2026- Developer of an AI-powered conversation analysis application designed to bring context and understanding to every medical conversation.
- Abridge is valued at approximately $6.7B (~$200/share on the secondary market) as of Oct 2026, up 26% since its later-stage round, Jun 2025, per PrivateMarketView’s mark.
- It has raised $758.0M across 3 recorded rounds; the latest was Later Stage VC (Series D) ($250.0M) in Feb 2025.
- Notable investors include Andreessen Horowitz, Mana Ventures, Soma Capital, Khosla Ventures, Lightspeed Venture Partners — 50 tracked in total.
- PrivateMarketView tracks 1 recorded secondary trades in Abridge shares.
- Status: Privately Held (backing).
Up 26% since its later-stage round, Jun 2025 ($5.3B post-money).
Membership and data by Private Market View
- ·The complete investor list: 50 names
- ·Watch Abridge: the Monday email on marks, rounds and moves
Secondary market
monthly marks · 34 months · Jan 2024 – Oct 2026Membership and data by Private Market View
Abridge secondary trades
1 on record · Dec 2025 – Dec 20251 trades between Dec 2025 and Dec 2025. Exact dates, prices and structures are available to Pro members.
Membership and data by Private Market View
Abridge funding rounds
3 roundsWho backs Abridge
50+Membership and data by Private Market View
Abridge valuation
Abridge is valued at approximately $6.7 billion as of Oct 2026. The figure is set by secondary market price. The secondary market quotes about $200 per share. The reference point is its later-stage round in Jun 2025, at a $5.3 billion post-money valuation; the current figure is up 26% since.
Abridge ranks 28th by valuation and 54th by capital raised among the private companies PrivateMarketView tracks.
How much has Abridge raised?
Abridge has raised $758 million across 3 recorded rounds since 2023. The largest was a $30 million Series B in Oct 2023; the most recent was a $250 million Series D in Feb 2025.
Abridge secondary market activity
1 secondary trade in Abridge shares is on record, in Dec 2025. Exact dates, prices and structures are available to Pro members.
A monthly secondary-market price series for Abridge runs from Jan 2024 to Oct 2026 (34 months).
Abridge investors
50 investors are on record for Abridge, including Andreessen Horowitz, Mana Ventures, Soma Capital and Khosla Ventures. By type, the record holds 19 venture capital firms and 3 growth equity firms. The Series D in Feb 2025 drew 15 investors.
Comparable companies
Comparable enterprise systems (healthcare) names by valuation on PrivateMarketView: Zelis Healthcare ($17 billion), Aledade ($3.5 billion) and Office Ally ($1.8 billion).
About Abridge
Developer of an AI-powered conversation analysis application designed to bring context and understanding to every medical conversation. The company's application uses machine learning to offer an audio-based system to record and summarize medical conversations, give insights and meaning to them, enabling users to follow through with the doctors' recommendations and to reduce administrative burden.
- Industry
- Enterprise Systems (Healthcare)
- Sector
- Software
- HQ
- Pittsburgh, PA, United States
- Founded
- 2018
- Employees
- 488
- Website
- abridge.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.